Tyra Biosciences, Inc. (TYRA) saw its shares plummet 5.08% during intraday trading on Tuesday, following analyst coverage initiation by Wolfe Research.
Wolfe Research began coverage of the biopharmaceutical company with a "Peer Perform" rating and did not assign a price target. The neutral "Peer Perform" rating suggests the analyst expects the stock to perform in line with its industry peers, which may have disappointed investors hoping for a more bullish outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.